Janney Raises Target on Repligen

Janney Capital Markets on Friday raised its price target on Repligen to $47 from $42 per share following the company’s acquisition of hollow fiber filtration provider Spectrum, which Janney said is a game changer.

In a note to clients, Janney analyst Paul Knight said that the deal would provide Repligen with revenue, margin and M&A upside, and will increase the company’s end-market exposure in vaccines, recombinant proteins and gene therapy.
The research firm maintained its buy rating on the stock. Shares were 7.5% higher in midday trade.

By Celina Yao